BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sessa M, di Mauro G, Mascolo A, Rafaniello C, Sportiello L, Scavone C, Capuano A. Pillars and Pitfalls of the New Pharmacovigilance Legislation: Consequences for the Identification of Adverse Drug Reactions Deriving From Abuse, Misuse, Overdose, Occupational Exposure, and Medication Errors. Front Pharmacol 2018;9:611. [PMID: 29946258 DOI: 10.3389/fphar.2018.00611] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Schifano F, Chiappini S, Corkery JM, Guirguis A. An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol 2019;22:270-7. [PMID: 30722037 DOI: 10.1093/ijnp/pyz007] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 20.5] [Reference Citation Analysis]
2 Herrera-Gómez F, García-Mingo M, Álvarez FJ. Benzodiazepines in the oral fluid of Spanish drivers. Subst Abuse Treat Prev Policy 2020;15:18. [PMID: 32093743 DOI: 10.1186/s13011-020-00260-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Stergiopoulos S, Fehrle M, Caubel P, Tan L, Jebson L. Adverse Drug Reaction Case Safety Practices in Large Biopharmaceutical Organizations from 2007 to 2017: An Industry Survey. Pharmaceut Med 2019;33:499-510. [PMID: 31933240 DOI: 10.1007/s40290-019-00307-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Mascolo A, Ruggiero R, Sessa M, Scavone C, Sportiello L, Rafaniello C, Rossi F, Capuano A. Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System. Front Pharmacol 2019;10:425. [PMID: 31114497 DOI: 10.3389/fphar.2019.00425] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Crescioli G, Lombardi N, Bettiol A, Menniti-Ippolito F, Da Cas R, Parrilli M, Del Lungo M, Gallo E, Mugelli A, Maggini V, Firenzuoli F, Vannacci A. Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. Br J Clin Pharmacol 2020;86:106-20. [PMID: 31656045 DOI: 10.1111/bcp.14140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
6 Hauser AS, Kooistra AJ, Sverrisdóttir E, Sessa M. Utilizing drug-target-event relationships to unveil safety patterns in pharmacovigilance. Expert Opin Drug Saf 2020;19:961-8. [PMID: 32510245 DOI: 10.1080/14740338.2020.1780208] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
7 Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®. Sci Rep 2019;9:7236. [PMID: 31076635 DOI: 10.1038/s41598-019-43715-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
8 Smirni D, Garufo E, Di Falco L, Lavanco G. The Playing Brain. The Impact of Video Games on Cognition and Behavior in Pediatric Age at the Time of Lockdown: A Systematic Review. Pediatr Rep 2021;13:401-15. [PMID: 34287345 DOI: 10.3390/pediatric13030047] [Reference Citation Analysis]
9 Carnovale C, Mahzar F, Scibelli S, Gentili M, Arzenton E, Moretti U, Leoni O, Pozzi M, Peeters GGAM, Clementi E, Medaglia M, Radice S. Central nervous system-active drug abused and overdose in children: a worldwide exploratory study using the WHO pharmacovigilance database. Eur J Pediatr 2019;178:161-72. [PMID: 30374752 DOI: 10.1007/s00431-018-3281-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Mascolo A, Scavone C, Bertini M, Brusco S, Punzo F, Pota E, Di Martino M, Di Pinto D, Rossi F. Safety of Anticancer Agents Used in Children: A Focus on Their Off-Label Use Through Data From the Spontaneous Reporting System. Front Pharmacol 2020;11:621. [PMID: 32457620 DOI: 10.3389/fphar.2020.00621] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
11 Liang D, Sessa M. Post-marketing safety surveillance of erenumab: new insight from Eudravigilance. Expert Opin Drug Saf 2022. [PMID: 35236231 DOI: 10.1080/14740338.2022.2049231] [Reference Citation Analysis]